Companies › Beijing Sungen Biomedical Technology
2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Oncology, Cardiovascular, Gastroenterology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SGC001 injection | – | Phase 2 | Acute Anterior ST-Segment Elevation Myocardial Infarction; Acute Pancreatitis | Apr 2027 |
| SGT003 | – | Phase 1 | Advanced Solid Tumor | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07306182 | SGC001 injection | Phase 2 | Acute Anterior ST-Segment Elevation Myocardial Infarction | Cardiovascular | Apr 2027 |
| NCT07803965 | SGC001 injection | Phase 2 | Acute Pancreatitis | Gastroenterology | Nov 2027 |
| NCT07811037 | SGT003 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2028 |
No annotated target.
–
Zhejiang Doer Biologics Salubris Biotherapeutics Institut de Recherches Internationales Servier (I.R.I.S.) Hinova Pharmaceuticals HighField Biopharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.